Pyroglutamyl aminopeptidase I (PAP-I, EC 3.4.19.3) is a typical cytosolic cysteine peptidase, displaying ubiquitous tissue distribution, and hydrolytically removes the L-pyroglutamate (L-pGlu) residue from the amino terminus of L-pGluproteins and peptides such as thyrotropin-releasing hormone (TRH), luliberin (LH-RH) and neurotensin. [1] [2] [3] [4] Cyclation of the N-terminal L-glutamic acid, namely the formation of LpGlu, allows the peptides to have a longer biological half-life than other peptides of similar size, since the majority of peptidases are not capable of hydrolyzing the L-pGlu-X bond. The physiological role of PAP-I currently remains unclear, but seems to be widely involved in the metabolism of LpGlu-containing bioactive peptides including TRH and LH-RH. 5, 6) Gene encoding human PAP-I has been recently cloned and expressed in Spodoptera frugiperda cells for characterization by Dando et al. 6) They demonstrated that the recombinant human PAP-I was enzymatically active and had properties similar to those of the naturally occurring mammalian enzymes reported previously. 7-9) However, the enzyme in rats, the species most frequently used in drug developmental experiments, has not been completely investigated yet.
Hydrolysis of Synthetic Substrate, L-Pyroglutamyl p-Nitroanilide is Catalyzed Solely by Pyroglutamyl Aminopeptidase I in Rat Liver Cytosol
product was radiolabeled with [a- 32 P]dCTP using Rediprime TM II (Amersham Biosciences). A rat liver lZAPII cDNA library (Stratagene) was screened with the plaque hybridization method. 10) The nucleotide sequence of rat PAP-I cDNA has been deposited in the DDBJ/EMBL/GenBank TM databases under Accession No. AB098134.
Construction of Bacterial Expression Vector and Expression of PAP-I in E. coli The total RNA from mouse liver was prepared as described above for rat liver. Human liver Poly A ϩ RNA was purchased from Clontech Laboratories Inc. The full-length clones were amplified by RT-PCR as described above using the primers PAPR3 (5Ј-GGATC-CATGGAGCAGCCGCGGAAAGC-3Ј) and PAPR4 (5Ј-TCAGAGCTGGTGGCAGCAGC-3Ј) for rat PAP-I, PAPM1 (5Ј-GGATCCATGGAGCAGCCGCGGAAGGC-3Ј) and PAPM2 (5Ј-TCAGAGCTGGCGGCAACAGC-3Ј) for mouse PAP-I, and PAPH1 (5Ј-GGATCCATGGAGCAGCCGAG-GAAGGC-3Ј) and PAPH2 (5Ј-TCAGTGTTTGTGGCA-ATAGT-3Ј) for human PAP-I. The PCR products were subcloned into a pGEM ® -T Easy Vector (Promega Corporation). The full-length clones were excised following BamH1/ EcoR1 digestion and subcloned into pGEX-6P-3 (Amersham Biosciences).
By infecting E. coli strain JM109 with each vector, rat, mouse and human PAP-Is were expressed and obtained each as a single protein using GST gene fusion systems (Amersham Biosciences) according to the manufacturer's instructions. The proteins obtained (recombinant PAP-I) were pure as judged by SDS-PAGE. The enzymes obtained were dissolved in phosphate buffered saline containing 2 mM DTT and 2 mM EDTA. The samples were stored frozen at Ϫ80°C until used. PAP-I activity was retained during the test period by storing under freezing conditions.
Purification of PAP-I from Rat Liver Cytosol All operations were performed at 4°C. The homogenate of male F344/DuCrj rat liver (194 g) was freshly prepared using three volumes of 10 mM potassium phosphate buffer, pH 7.4, containing 1.15% potassium chloride. The homogenate was centrifuged at 105000 g for 1 h and the supernatant was fractionated by ammonium sulfate precipitation at 30 to 50% saturation. The precipitate was dissolved in a small volume of 20 mM Tris-HCl buffer, pH 7.4, containing 2 mM DTT and 10% glycerol (referred to as buffer A), and this solution was desalted by gel filtration. The desalted solution was applied to a column (5ϫ11 cm) of DEAE-Sephacel (Amersham Biosciences), which had been equilibrated with buffer A. After the column was washed with the same buffer, the enzyme activity was eluted with potassium chloride in buffer A increasing the salt concentration linearly from 0 to 0.35 M. Fractions containing the enzyme activity were pooled. The pooled fraction was concentrated and applied to a gel filtration column (HiLoad TM 26/60 Superdex TM 75 pg, Amersham Biosciences), which had been equilibrated with buffer A containing 100 mM potassium chloride. The enzyme activity was eluted from the column with the same buffer and the active fractions were combined. The combined fraction was concentrated and the buffer in this solution was changed to 1 mM potassium phosphate buffer (pH 7.4) containing 2 mM DTT and 10% glycerol (hereafter referred to as buffer B). This enzyme fraction was applied to a column of hydroxylapatite (CHT2-I, 2 ml, Bio-Rad), which had been equilibrated with buffer B. After the column was washed with the same buffer, the enzyme activity was eluted by increasing the phosphate concentration in buffer B linearly from 1 to 100 mM. The active fractions were combined, concentrated, and the buffer in the combined fraction was changed to buffer B. This fraction was subjected to further purification by the 2nd CHT2-I column chromatography as above. The enzyme fractions were combined, concentrated and stored frozen at Ϫ80°C until used.
Molecular Weight Determination The relative molecular weight was determined by gel filtration chromatography using a HiLoad TM 26/60 Superdex TM 75 pg. A Low Molecular Weight Gel Filtration Calibration Kit (Amersham Biosciences), consisting of bovine serum albumin (MW: 67000), ovalbumin (MW: 43000), chymotrypsinogen A (MW: 25000) and ribonuclease A (MW: 13700), was used as the molecular weight standard. The elution buffer used was buffer A without DTT and containing 100 mM potassium chloride.
Measurement of PAP-I Activity Potassium phosphate buffer (10 mM, pH 7.4) containing 1 mM dithiothreitol (DTT) and an appropriate amount of each enzyme source (45 ml) was preincubated at 37°C for 2 min, and the reaction was started by the addition of 5 ml of 200 mM L-pGlu-pNA (final concentration: 20 mM). After incubation of the mixture for 5-20 min at 37°C, the reaction was stopped by the addition of acetonitrile containing 0.25 mM of phenacetin as the internal standard for determination of pNA by LC tandem mass spectrometry (LC/MS/MS). The mixture was centrifuged at 20000 g for 2 min at 4°C and the supernatant was stored at 4°C until analysis. In a separate experiment it was confirmed that the pNA produced was stable during the testing period.
The optimum pH for the enzyme was determined at the substrate concentration of 20 mM over a pH range of 5-9 using 100 mM potassium phosphate buffer for pH 5-7.4 and 100 mM Tris-HCl for pH 7.4-9.
A SCIEX API-III Plus (Perkin Elmer Japan Co., Ltd.) connected to an LC-10A system (Shimadzu Corp.) was used as the LC/MS/MS system for measurement of pNA. The column used was a CAPCELL PAK C18 UG120Å (2.0 mm I.D.ϫ150 mm, Shiseido Co., Ltd., Tokyo, Japan). A mixture of acetonitrile and water (75 : 25, v/v) containing 1 mM ammonium acetate was used as the mobile phase. Protonated molecular ion, [MϩH] ϩ , (pNA: m/zϭ139, phenacetin: m/zϭ180.1) was selected as the precursor ion, and the product ion (pNA: m/zϭ122, phenacetin: m/zϭ110) was monitored. The detection limit of pNA was 0.2 mM.
Additional Peptidase Assay The rate of enzymatic hydrolysis of L-Leu-pNA, L-Ala-pNA and L-Pro-pNA (final concentrations: 1 mM in 50 mM potassium phosphate buffer, pH 7), known substrates of many peptidases, was assayed at room temperature after addition of the enzyme solution by colorimetric determination of pNA at 410 nm (eϭ8800).
Protein Determination Protein concentrations were determined according to the dye-complex method reported by Bradford 11) or according to Lowry's method 12) using DC Protein Assay Kit (Bio-Rad). Bovine serum albumin was used as a standard.
Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) SDS-PAGE was performed on 12.5% or 10-20% gel according to the method of Laemmli.
13) Protein bands were stained with SYPRO ® Ruby protein gel stain (Molecular Probes Inc.).
Protein Identification
The protein bands were excised from the gel stained with SYPRO ® Ruby. In-gel digestion of the protein using sequencing grade modified trypsin (Promega) was performed essentially according to the method by Shevchenko et al. 14) The resultant proteolytic peptides were analyzed by nano-LC/MS/MS to collect the peptide sequence information. A Q-TOF 2 hybrid mass spectrometer (Micromass) equipped with a nano-electrospray ion source (nano-ESI) was used as the nano-LC/ESI-MS/MS system. Subcellular Fractionation of Rat and Mouse Tissue Homogenates Male F344/DuCrj rats and male C57BL/6J mice were sacrificed and the excised tissues were homogenized in 10 mM potassium phosphate buffer (pH 7.4) containing 1.15% potassium chloride. Subcellular fractionation of the homogenates was performed according to the method of Tanaka et al. 15) Immunoblot Analysis The polyclonal antibody against the rat PAP-I recombinant protein purified from E. coli was raised in rabbits according to Nakamura et al. 16) The antiserum was further purified by passing through a Protein A column (NGK Insulators, Ltd.), and the IgG fraction was obtained. SDS-PAGE of denatured samples (7 mg protein) was performed on 10-20% gels. Immunoelectrophoretic (Western) blot analysis was carried out with polyvinylidene fluoride (PVDF) membranes (Immobilon, Millipore), and the protein was detected by the enhanced chemiluminescence detection method (Phototope-HRP Western Blot Detection Kit, Cell Signaling Technology, Inc.).
RESULTS
cDNA Cloning and Expression of Rat, Mouse and Human PAP-Is We cloned cDNA encoding rat PAP-I by screening the rat liver cDNA library using a probe which was prepared by RT-PCR. The rat PAP-I cDNA was 939 bp in length with 627 bp comprising the open reading frame. The predicted translation product of the rat PAP-I cDNA encodes a protein of 209 amino acids with a calculated molecular weight of 22913 Da (Fig. 1) .
The amino acid sequence was highly conserved among rat, mouse and human PAP-Is. The homology of the deduced amino acid sequence of rat PAP-I was 98.6% to mouse PAP-I and 94.3% to human PAP-I (Fig. 1) . The amino acid sequence between rat and human PAP-Is was mainly different in a part of the C-terminal amino acid residues.
Mouse and human PAP-I cDNAs were prepared by PCR cloning based on the respective cDNA information, and these cDNAs as well as rat PAP-I cDNA were each inserted into a bacterial expression vector to express the enzyme proteins in E. coli. The yields were 7-9 mgP/l E. coli culture. The molecular weights of the rat, mouse and human PAP-I expressed in E. coli were calculated to be approximately 25 kDa by both SDS-PAGE and gel filtration chromatography, showing that the rat, mouse and human PAP-Is are all monomeric enzymes.
Purification of Rat Liver PAP-I Using anion-exchange, gel-filtration, 1st hydroxylapatite and 2nd hydroxylapatite column chromatographies, PAP-I was purified 1762-fold from rat liver homogenate with an overall yield of 1% (Table  1 ). This purified fraction did not show any hydrolyzing activities toward L-Leu-pNA, L-Ala-pNA or L-Pro-pNA, general substrates for many other known peptidases, indicating that the enzyme fraction was free from other peptidases. SYPRO ® Ruby gel staining of the purified enzyme after SDS-PAGE showed two protein bands. Both the elution profile of the activity and the density of the bands on SDS- PAP-I activities using L-pGlu-pNA as a substrate and other esterase activities using various substrates were determined as described in Materials and Methods. CHT2-I: Hydroxylapatite, LpNA: L-Leu-pNA, ApNA: L-Ala-pNA, PpNA: L-Pro-pNA, -: not determined, n.d.: not detected. PAGE in the last chromatography indicated that the upper band is PAP-I. The molecular weight of the purified PAP-I was 23.4 kDa by gel filtration chromatography and was 25 kDa by SDS-PAGE, indicating that rat liver PAP-I exists as a monomer. This molecular weight is comparable to recombinant PAP-Is and the values previously reported for the enzymes purified from various mammalian tissues. 8, [17] [18] [19] [20] Amino Acid Sequence Analysis of Peptide Fragments for Identification of Rat Liver PAP-I In-gel digestion of the two protein bands in the purified PAP-1 preparation was performed, and the peptide fragments were analyzed by nano-LC/ESI-MS/MS. The peptide sequences obtained from the upper band (LGLGDSVDLHVYEIPVEYQTVQR, LI-PALWEK and SAFVHVPPLGKPYNADQLGR) were identified to the sequence of the rat PAP-I, demonstrating that the upper protein band was PAP-I.
The lower protein band whose molecular weight was estimated to be 24 kDa by SDS-PAGE was identified to be a protein found in the EST database at NCBI (H32616) with unknown function. There was no amino acid sequence homology between rat PAP-I and the H32616 protein but difficulty in separating PAP-I from this protein in column chromatography may be due to a strong affinity of the protein to PAP-I leading to a possible complex formation. However, investigating the fractions containing two protein bands in each chromatography in detail, there was a tendency of separation of PAP-I from this protein, suggesting that the two proteins merely possess a very similar affinity to each column and the complex formation is unlikely (data not shown).
Characterization of Purified and Recombinant PAP-Is
The K m value for the purified rat liver PAP-I in hydrolyzing L-pGlu-pNA was 0.030 mM ( Table 2 ). The K m values for recombinant rat, mouse and human PAP-Is expressed in E. coli were 0.054, 0.038 and 0.038 mM, respectively, being very similar to that of the purified rat liver PAP-I. The V max values for recombinant rat, mouse and human PAP-Is were 17.7, 8.0 and 10.8 mmol/min/mgP, respectively, and 5.4 mmol/min/mgP for the purified rat liver PAP-I.
The effects of various peptidase inhibitors (1 mM) on the activities of the purified rat liver PAP-I and recombinant rat, mouse and human PAP-Is were investigated at a substrate (LpGlu-pNA) concentration of 20 mM. As shown in Table 3 , the inhibition profiles were almost the same among the four PAP-I preparations. Typical serine peptidase inhibitors (DFP and PMSF) and chelating agents (EDTA and 1,10-phenanthroline) did not inhibit the enzyme activity at all. The leucine aminopeptidase inhibitor (bestatin) also had no effect. On the other hand, typical inhibitors of thiol-dependent enzymes (NEM and PCMB) completely inhibited the activities of the four PAP-I preparations. However, a more selective inhibitor of cysteine peptidases of the papain family (E-64) did not inhibit the enzyme. TRH, a PAP-I substrate, showed strong inhibition, decreasing the enzyme activity to approximately 10%. Zn 2ϩ and Co 2ϩ , known inhibitors of PAP-I, were both inhibitory, but Mg 2ϩ and Mn 2ϩ were not. Similar results were obtained at an inhibitor concentration of 0.2 mM (data not shown).
The optimum pHs for recombinant rat, mouse and human PAP-Is were 8, 8.5 and 8.5, respectively, and 8.5 for the purified rat liver PAP-I.
Subcellular Localization of PAP-I in Rat Liver and Its

Distribution in Rat Tissues
In the rat liver, the PAP-I activities, assayed using L-pGlu-pNA as the substrate, in the nuclear, mitochondrial, cytosolic and microsomal fractions were 0.006, 0.012, 0.438 and 0.004 nmol/min/mgP, respectively, showing that the PAP-I activity was localized in the cytosolic fraction. The PAP-I activities in the cytosolic fractions from the kidneys, testis, aorta, brain, lungs, heart, small intestine and muscle were 1.317, 0.061, 0.021, 0.062, 0.120, 0.031, 0.030 and 0.019 nmol/min/mgP, respectively. The results indicated that the kidneys and liver showed relatively high activities compared with the other tissues and organs. The fractions (7 mg protein) were separated on a 10-20% polyacrylamide SDS gel and then subjected to immunoelectrophoretic blot analysis with an antibody against recombinant rat PAP-I. Lanes 1-5: rat liver, Lanes 6-7: mouse liver, Lanes 8-9: human liver; Lane 1, whole homogenate; Lane 2, nuclear fraction; Lane 3, mitochondrial fraction; Lanes 4, 6, 8, cytosolic fraction; Lanes 5, 7, 9, microsomal fraction.
There was no activity in the plasma.
Immunoblotting Analysis of Rat, Mouse and Human Liver Subcellular Fractions by Antibody The whole homogenate and the nuclear, mitochondrial, cytosolic and microsomal fractions of rat liver were analyzed by immunoblotting using an antibody raised against recombinant rat PAP-I in rabbits (Fig. 2 ). An immunoreactive band with an expected size of 25 kDa was detected most intensely in the whole liver homogenate and the cytosolic fraction. The immunoreactive band was also found in the cytosolic fractions of the mouse and human liver (Fig. 2) .
Effects of Antibody on L-pGlu-pNA Hydrolyzing Activity The effects of the antibody on the hydrolysis of L-pGlupNA (20 mM) were examined in rat, mouse and human liver cytosols ( Table 4 ). The control hydrolyzing activities toward L-pGlu-pNA in rat, mouse and human liver cytosols were 0.46, 0.32 and 0.20 nmol/min/mgP, respectively. The hydrolyzing activities in rat and mouse liver cytosols were completely inhibited by the addition of the antibody at a concentration of 1 mgP/ml. The control IgG did not affect the hydrolyzing activities at all.
DISCUSSION
We obtained the cDNA encoding rat PAP-I from the rat liver cDNA library using primers designed according to the conserved region of the cDNA sequence of the mouse and human PAP-Is in GenBank TM . The rat PAP-I cDNA encoded a protein of 209 amino acids with a calculated molecular weight of 22913 Da. The homology of the deduced amino acid sequence of rat PAP-I was 98.6% to mouse PAP-I and 94.3% to human PAP-I, showing that the amino acid sequence is highly conserved among all the three species.
The peptide fragments obtained by trypsin digestion of PAP-I purified from rat liver cytosol were identical to those parts of the amino acid sequence of recombinant rat PAP-I. Consistently, the biochemical properties of the purified rat liver cytosolic PAP-I were almost identical to those of recombinant rat PAP-I in terms of the molecular weight, subunit structure, affinity to the substrate, inhibitor profile and pH optimum, and agreed well with those of the enzymes reported for several other mammalian tissues, such as guineapig brain, 17) human kidneys and skeletal muscle, 18, 19) rat adenohypophysis 20) and bovine brain. 8) Serine protease inhibitors and metal chelating agents typically had no effect on the enzyme activity, but cysteine protease inhibitors, i.e. thiol-blocking agents such as NEM and PCMB, showed potent inhibitory activity, demonstrating that this enzyme is a thiol-dependent enzyme. However, E-64, a selective inhibitor of cysteine peptidases of the papain family, did not inhibit the enzyme activity. This finding was interesting because the active site of papain (Cys-His-Asp) 21 ) is very similar to that of PAP-I as described below. Similar results for E-64 were also obtained for purified bovine brain PAP-I 6) and recombinant human PAP-I. 8) Genes encoding bacterial PAPs have been cloned and expressed for their characterization. 22, 23) Studies using the techniques of site-directed mutagenesis and X-ray crystallography have established that Cys144, His168 and Glu81 (numbering for PAP in Bacillus amyloliquefaciens) comprise a catalytic triad. 22, 24, 25) Dando et al. 6) reported that the overall sequence homology between bacterial PAPs and mouse and human PAP-Is appears to be relatively low, but the catalytic triad sequence, Cys149-His168-Glu85 (numbered according to human PAP-I) was fully conserved among all the species. This putative catalytic triad sequence was also conserved in rat PAP-I.
Western blot analysis showed that the immunoreactive band of PAP-I at the expected size of 25 kDa was detected most intensely only in the cytosolic fractions of the liver, being consistent with the subcellular localization of the hydrolyzing activity. Moreover, the hydrolyzing activities of LpGlu-pNA in rat and mouse liver cytosolic fractions were both completely inhibited by the antibody against recombinant rat PAP-I, indicating that PAP-I is solely involved in the hydrolysis of the amide bond of L-pGlu-pNA in the liver cytosol. Note, however, that there still remains the possibility of the existence of the enzymes which crossreact with the antibody against recombinant rat PAP-I, as the antibody used was the IgG fraction, not the purified antibody.
The terminal L-pGlu residue is thought to donate a more or less xenobiotic nature to the peptides leading to resistance to hydrolysis by various peptidases. Since PAP-I recognizes only the L-pGlu structure, ignoring the rest of the amino acid sequence, we hypothesized that PAP-I, as a xenobiotics-metabolizing enzyme, will hydrolyze other L-pGlu-containing xenobiotics with a low molecular weight. Among candidate compounds having this chemical structure, we have found several xenobiotic PAP-I substrates as will be reported elsewhere. It will be also interesting to investigate the xenobiotic compounds having glutamyl moiety instead of the pGlu moiety to understand the importance of pGlu structure as the substrate of PAP-I, and future studies should be awaited. and many valuable discussions.
